ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

BACKGROUND: Therapies targeting multiple survival pathways are desirable for high-grade gliomas. TG02 (Zotiraciclib), a CDK9 inhibitor, regulates transcription and metabolism of tumor cells and synergizes with temozolomide. A phase I/II trial was launched to test the TG02/temozolomide combined treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wu, Jing, Bryla, Christine, Su, Yu-Ting, Grajkowska, Ewa, McCoy, Ann, Boris, Lisa, Antony, Ramya, Garren, Nancy, Siegel, Christine, Cordova, Christine, Aboud, Orwa, Vera, Elizabeth, Lawhon, Tracy, Penas-Prado, Marta, Theeler, Brett, Mendoza, Tito, Armstrong, Terri, Yuan, Ying, Gilbert, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847568/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.104
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados